Legend Biotech Corp: Form 20-F for the period ended Dec 31, 2020
Filed with the SEC on Apr 2, 2021 and accepted by EDGAR at Apr 2, 2021, 08:10 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2020-01-01 to 2020-12-31 | $75.7m | ifrs-full:Revenue |
| Income tax | 12 months2020-01-01 to 2020-12-31 | −$4.1m | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months2020-01-01 to 2020-12-31 | −$303.5m | ifrs-full:ProfitLossAttributableToOwnersOfParent |
| Diluted EPS | 12 months2020-01-01 to 2020-12-31 | −$1.28 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months2020-01-01 to 2020-12-31 | −$1.28 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months2020-01-01 to 2020-12-31 | −$223.0m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months2020-01-01 to 2020-12-31 | $45.7m | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | At period end2020-12-31 | $455.7m | ifrs-full:CashAndCashEquivalents |
| Current assets | At period end2020-12-31 | $592.9m | ifrs-full:CurrentAssets |
| Total assets | At period end2020-12-31 | $721.0m | ifrs-full:Assets |
| Current liabilities | At period end2020-12-31 | $161.2m | ifrs-full:CurrentLiabilities |
| Total liabilities | At period end2020-12-31 | $440.8m | ifrs-full:Liabilities |
| Shareholders' equity | At period end2020-12-31 | $280.3m | ifrs-full:EquityAttributableToOwnersOfParent |
| Shares outstanding | At period end2020-12-31 | 266,010,256 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001564590-21-017439. Last ingested by Listed: Nov 5, 2026, 13:56 ET. Listed shows no prices and gives no investment advice.